Podcasts about mikhael

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smoldering multiple myeloma, transplant eligible multiple myeloma, transplant ineligible multiple myeloma, and relapsed or refractory multiple myeloma. They highlight the importance of shared decision making and patient-centric care. They comment on the explosion of new treatment options in this space and the impetus for this guideline becoming a living guideline, which will be updated on an ongoing, regular basis. Read the full guideline, "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline" at www.asco.org/hematologic-malignancies-guidelines. TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/hematologic-malignancies-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02587   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lisa Hicks from St. Michael's Hospital and University of Toronto, and Dr. Joseph Mikhael from the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, co-chairs on "Treatment of Multiple Myeloma: American Society of Clinical Oncology-Ontario Health (Cancer Care Ontario) Living Guideline." Thank you for being here today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: Thanks so much. Dr. Joseph Mikhael: It is a pleasure to be with you, Brittany. Thank you. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Hicks and Dr. Mikhael who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Mikhael, I would like to start by recognizing that this guideline updates the 2019 ASCO-CCO Guideline on the Treatment of Multiple Myeloma. So what prompted this update and what is the scope of this updated guideline? Dr. Joseph Mikhael: It is amazing when we think back in myeloma years, 2019 actually seems a very, very long time ago because really so much has changed in myeloma over these last six to seven years. Indeed, there have been over 150 randomized controlled trials that we didn't have at the prior guideline that we reviewed for this. Myeloma is a disease that has really changed so dramatically over these last several years. Multiple new agents have been introduced. We now have CAR-T cell therapy, bispecific antibodies, and multiple other agents that were not available at the time. Furthermore, with this growing complexity, it is becoming more important than ever to be able to provide practical advice and guidelines to the oncology community. For most oncologists, they have less than 5% of their time dedicated to multiple myeloma. It is important to bring a clarity to them that allows them to care for their patients. And the scope of these guidelines, furthermore, really cover the whole spectrum of myeloma. They go further than our prior guideline where now we have included smoldering multiple myeloma along with frontline therapy and relapsed multiple myeloma. So, we have really tried to provide the full spectrum to our colleagues in oncology to ensure that they have the tools they need to provide the best care possible for their patients. Dr. Lisa Hicks: That is a really terrific summary. And maybe one thing I will just add is it is really unique to have this much literature. I can't think of another guideline that I have ever been involved with that has seen a field move so quickly and develop so many advancements in a period of just over four or five years. Brittany Harvey: Certainly, there is a large volume of evidence that you all had to review for this guideline update. I think to your point probably one of the greater volumes of literature for a guideline update that you both mentioned. Based on that, I would like to review the key recommendations that are updated in this guideline. So Dr. Hicks, that new patient population that Dr. Mikhael mentioned earlier, what are the key recommendations for patients with smoldering multiple myeloma? Dr. Lisa Hicks: So this is the first time that an ASCO guideline is addressing this branch of multiple myeloma care. It is an area where I think some guidance is needed, and smoldering myeloma is not an active cancer. And so one thing that I really want to highlight is that the panel felt very strongly that to recommend any therapy in this space we needed a higher level of evidentiary certainty, of evidentiary confidence, to make recommendations for active therapy. The panel really made two very important recommendations. First of all, the panel did not recommend treatment for low or intermediate risk smoldering myeloma. That is important. And then the area where I think for the first time we have recommended consideration of treatment is patients with high risk smoldering myeloma. And for patients with high risk smoldering myeloma, the panel recommended that it was appropriate to consider either treatment with daratumumab or careful observation. Dr. Joseph Mikhael: And I think that move forward as you have mentioned, Dr. Hicks, is particularly important because it is an area to some degree still of equipoise and many trials are going on in the area. But we do now have a strong phase III trial that supports the use of daratumumab monotherapy for three years when compared to close observation. But of course, that is not for everyone. And one of the key themes of all of our recommendations are going to be now that more and more choices are available, that we have discussions with our patients to ensure that we match the right treatment with the preference of the patient. And I think that is particularly important here in smoldering myeloma. Dr. Lisa Hicks: Multiple myeloma care and the multiple myeloma evidence is really so nuanced, and one of the nuances that readers will appreciate if they read the guideline is that how smoldering myeloma is risk stratified has been different across different trials. And that really adds to the complexity of this recommendation and is one of the reasons that the panel felt that it was appropriate to recommend either observation or treatment. Brittany Harvey: It is great to have these new recommendations for this unique patient population. And as you both mentioned, that individualized patient care is really important across this entire guideline. So then following those recommendations, Dr. Mikhael, what is recommended for initial therapy, autologous stem cell transplantation, post transplant therapy, and measurement of response for patients with transplant eligible multiple myeloma? Dr. Joseph Mikhael: Well, that is an area that has really considerably also grown since the last guideline. Obviously one would have to consult the guidelines to get every last detail, but in essence, we want to assess whether or not patients are transplant eligible or ineligible. And that assessment is not based on age or renal function alone, but indeed on a careful assessment of that patient. When that assessment is made and deemed that a patient is transplant eligible, our recommendation is that a patient typically would receive a quadruplet. That is to say, a monoclonal antibody directed against CD38, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone to be given for approximately four to six cycles followed by the stem cell transplant, followed by potentially another two cycles of consolidation, and then maintenance therapy. A couple of important caveats. One, we do have two different CD38 antibodies that can be used, either daratumumab or isatuximab. Although typically bortezomib is the preferred proteasome inhibitor, consideration can be given to carfilzomib by virtue of the potential toxicity from bortezomib. And then lastly in the maintenance setting, we are typically recommending at least lenalidomide alone, but consideration can be given to dual maintenance therapy as the data is emerging to either add to that daratumumab or carfilzomib. All the while using the IMWG criteria for response. The goal of course is to achieve the deepest response possible and to maintain that response until such time as patients would relapse. Finally, the length of maintenance therapy continues to be an area of equipoise and study in multiple myeloma. And so at minimum, patients would receive two to three years of maintenance therapy, and based on risk status and depth of response it can be considered that patients would potentially come off maintenance therapy, of course always with the caveat that toxicity would influence length of therapy as well. Brittany Harvey: Yes, as you mentioned, evaluating which patients are eligible is extremely important for considering what is recommended in the guideline for both transplant eligible and transplant ineligible patients. So then Dr. Hicks, following those recommendations for transplant eligible multiple myeloma, what are the recommended treatments, goals of therapy, and measurement of response for patients with transplant ineligible multiple myeloma? Dr. Lisa Hicks: You know, I really can't emphasize enough how important an individualized patient assessment is. When we are thinking about the range of patients that are included in this category of transplant ineligible patients, it is a huge range. You may have fairly fit patients in their late 70s all the way to patients in their 90s. And we really want to see that treatments are tailored both to the fitness of the patient, their individual circumstances, and their preferences. And it is a wonderful thing to have lots of options for patients in this circumstance. What the guidelines have recommended for most patients who are transplant ineligible but fit enough for a stronger therapy is quadruplet therapy. So actually therapy that is very similar to what is being recommended in the transplant eligible population but for a longer period of time. And then for those patients who for whatever reason, be it their fitness or their preference, are not appropriate for that quadruplet therapy, the recommendation is for triplet therapy with a combination of lenalidomide, bortezomib, dexamethasone, or very often, more often in most cases, an antibody based approach with an anti-CD38 plus lenalidomide plus dexamethasone. Dr. Joseph Mikhael: The only thing I would add to that, I think we have to also, as we do mention in our recommendations, be particularly cautious with the dosing of these medications. Because even though we think of them as a single agent or a particular class, there can be quite a variation within the dosing regimen that can affect a patient's side effects and their quality of life. And so being very careful with dose modifications, and particularly in the transplant ineligible patient, is an important part of the recommendation as well. Dr. Lisa Hicks: Yeah, this is a podcast so no one can see me nodding vigorously that dose modification is so important particularly with those older and frailer patients, and with particular attention to trying to reduce dexamethasone doses and favoring weekly administration of bortezomib when that drug is used. Brittany Harvey: Absolutely. Considering the risks and benefits and patient preferences is really key to selecting therapy for these patients. So then Dr. Mikhael, for the final overarching patient population addressed in this guideline, for patients with relapsed or refractory multiple myeloma, what treatment options are recommended? Dr. Joseph Mikhael: This of course is, if you will, the biggest part of the guideline because there has been so much done in the relapse setting. And I think we start the guideline by saying a decision has to be made as to when to institute therapy. That there may be some patients with slow biochemical relapse that may be monitored for a period of time. But when the decision is made to initiate treatment, instead of a simple algorithm, the guideline emphasizes the fact that there are multiple choices that can be given to a patient that are going to match what comorbidities the patient has, what they have been treated with before, and of course what their preferences are. I think we highlight two particular areas. That now that CAR-T cell therapy is available as early as first relapse, it should be a consideration by virtue of the fact that it has resulted in such deep and durable responses. But that triplets should also be considered in that earlier relapse setting because we do have multiple classes of agents that can be used. We know that in later relapse options exist including bispecific antibodies for which we have four different choices. And that in general, patients will ultimately receive either a triplet or CAR-T cell therapy in earlier relapse, but there are some patients who may be eligible only for a doublet by virtue of their comorbidities and of their prior therapies. Lastly, it really does emphasize the point as we have mentioned a few times in this podcast, and I am so glad it keeps coming up, is that as I often say we don't treat myeloma, we treat people. And engaging the patient in that conversation to ensure that the right treatment gets matched to the right patients is particularly important because with all the new classes that we have with antibody drug conjugates, with XPO1 inhibitors, the traditional three classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, along with as we have already mentioned CAR-T and bispecific antibodies, it really is an incredible laundry list of choice. And making that choice specific to the patient becomes absolutely critical. I should also lastly note that there are patients who may defer their initial transplant. There may be patients who may be eligible for a second transplant. So autologous stem cell transplant, although primarily used in the frontline setting, may still be a consideration for a smaller subset of patients in the relapse setting. Dr. Lisa Hicks: I think maybe one thing that I would add is an overarching principle which is actually similar to a principle in the first guideline, and that is that in the relapsed or refractory setting, there are many different treatment options. And in fact, the number of treatment options feels like it is evolving every day. But an overarching principle for clinicians to consider is to try and choose combinations of drugs that the patient has either not been exposed to in the past or certainly that they are not refractory to. We really want to be pulling new options out of the toolbox as much as we can. Dr. Joseph Mikhael: Very often we do see where someone may be on a triplet and they are progressing on it and someone just changes out one drug. We have suggested not to take that approach but to take the approach of completely introducing a new therapy when someone is progressing on their current therapy. I think that point is particularly important and the consensus panel was very clear. Brittany Harvey: Understood. That is very helpful when thinking about what options to offer to patients in the relapsed and refractory setting. And as you mentioned earlier, the figures in this guideline provide an outline of options and then the tables really go into some of the details and outcomes of the trials, and those are very helpful for clinicians to refer to. So then Dr. Hicks, we have talked a little bit about some of the nuances of the guideline, but what should clinicians know as they implement these new and updated recommendations? Dr. Lisa Hicks: I think they should feel comfortable that these are trustworthy guidelines. So these are evidence-based guidelines that have been rigorously developed after a very thorough evidence review and put together by a panel of experts who were extremely thoughtful in their review of the evidence. And so all of this contributes to the trustworthiness of the guidance. And then I would also encourage people to take a deep look at the guidelines because of the importance of nuance that is addressed in them, and then to also explore some of the tools that ASCO is developing that helps with implementation including the flow charts that are contained within the guidelines and some additional tools that are available online. Brittany Harvey: Absolutely. The tools and resources for this guideline are available online with the publication and we will provide links to that in the show notes of the episode. So then following that, Dr. Mikhael, how does this guideline update affect patients with multiple myeloma? Dr. Joseph Mikhael: As we sort of intimated earlier, I like to say I don't treat myeloma, I treat people. I think we should always be patient-centric and patient-focused. And I think in the discussion we always were. We always wanted to ensure that multiple factors go into a decision-making process. We are not just looking at the biology of the disease, we are looking at patient factors. Those patient factors include their frailty as we commented in a frailty assessment, their preferences, their comorbidities. And I think, in a day where we have so many choices, we emphasize in the guideline the importance of that conversation with the patient. That, if you will, shared decision-making model where options are laid out and based on the patient factors and the treatment factors they can then be meshed together in the best way so that patients can make the right choice. And of course in conjunction with the guidelines, we have patient friendly summaries of them. And we involved, of course, patients in the development of these guidelines. And I think that is one of the greatest strengths of the ASCO guidelines is that there is a patient with us at the table who is giving their perspective on the guideline as we go forward. So I am very thankful that we have created a product that is, if you will, not only for the providers, the practitioners that are prescribing these agents and that are directly giving the care, but indeed for the very patients who of course have the most at stake here. Dr. Lisa Hicks: Yeah Joe, I am so glad you called out the participation of patient partners in the guideline. It is such an important part and they were really- the patient partner was such an important part of this panel in helping us understand the patient perspective as we developed this guidance. Brittany Harvey: Definitely. It is a hugely important role for the panel and for all of the panel including the patient partners and the experts in the disease to review the evidence and come up with comprehensive recommendations. And yes, as you mentioned, the individualized treatment and the shared decision-making is really paramount to this guideline. Finally, Dr. Hicks, you alluded to earlier the vast number of treatment options that is really exploding in multiple myeloma. And so this guideline is becoming a living guideline continuously updated by ASCO. So what are the outstanding questions regarding this topic and what evidence is the panel looking forward to for future updates? Dr. Lisa Hicks: I am really excited about this. This is one of the first guidelines that will be a living guideline for ASCO and it is such a good fit. You have heard Joe and I say a few times how quickly this field is moving, how complex the field is. I think everyone on the panel knew that no matter how quickly we did it and how deeply we reviewed the evidence, it was inevitable that more evidence would be generated as we were putting out the guideline. In a field like that, it is really important that we find a way to provide evidence-based guidelines quickly to the community. You know, waiting another five years, letting another 150 trials accrue before we do another guideline is not what the community needs. And so ASCO has really risen to this challenge and is committed to living guidelines. And so a living guideline is a guideline that commits to reviewing the evolving evidence on an ongoing basis, watching for practice changing trials, and having a standing panel that will review evidence and update recommendations on a regularly scheduled basis. So that is what a living guideline is, and that is what this guideline is becoming. That is just the first thing in terms of what a living guideline is. And then what are we watching? Well, honestly what aren't we watching? There is so much happening in multiple myeloma. We knew as we put the guideline out that there were trials in process, some trials that had been released at conferences but not yet published. We will be waiting for those and if they are practice changing they will be addressed in upcoming updates. There is new evidence just recently presented around combined anti-CD38 and bispecific antibodies. I don't know yet whether that will be addressed but I wouldn't be surprised if it was. There are so many things coming down the pipeline and it is just wonderful that there is going to be a way to try and address them in a robust fashion. Dr. Joseph Mikhael: Yeah I agree with you, Lisa. I can't think of another disease that would be more relevant for a living guideline. I mean we had difficulty because new data kept coming in as we were making recommendations. And so at some point we had to draw a line and say this is where we will stop and produce this guideline and have it ongoing. And I really look forward to seeing the updates because we know as you mentioned that there are so many things that are on the verge of approval and on the verge of changing the way we manage this terrible disease. And before I close, I would love to remind all of our listeners that as we commented from the start, patient engagement is critical at ASCO and in our guidelines process. Unfortunately we lost a very dear patient during the guidelines process, and that is Jack Aiello. Jack Aiello had been a patient and a patient advocate for many, many years in the myeloma community. And indeed we have actually dedicated these guidelines to his honor. And so I thought it would be valuable for us to mention that today. And we miss you Jack, but we are very grateful that we have been able to dedicate this excellent body of work to your memory. Brittany Harvey: Absolutely. This guideline and your dedication to him is an honor to his memory and we really recognize him in thinking about this guideline. We will look forward to those future trial results that you mentioned, Dr. Hicks, to update this guideline and continue to provide options for patients with multiple myeloma and improve upon those options and shared decision-making with patients. So I want to thank you both for all of your work to develop this guideline and for your time today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: You are so welcome. Thanks for featuring this guideline. Dr. Joseph Mikhael: Thank you so much, Brittany. It has been a privilege. Brittany Harvey: Finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/hematologic-malignancies-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, which is available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode of the REB Business Empowerment Showcase, REB deputy editor Emilie Lauer sits down with A Home for All chair and LJ Hooker CEO Christine Mikhael and committee member Natalie Hortz to discuss how the industry is coming together to address the nation's homelessness crisis. Mikhael and Hortz discuss the foundation's rapid progress, raising over $1 million in just two months, and highlight the often-overlooked realities of hidden homelessness, including couch surfing, living in cars, or moving between temporary accommodations. The conversation also delves into domestic and family violence as a key driver of homelessness, and how the foundation is carefully directing resources to make the most difference for women and children in need. The episode closes with a call to action for real estate professionals and beyond, exploring ways to get involved from fundraising and volunteering to immersive awareness events like "A Night Without Home".

In this episode of Mission Matters, Adam Torres interviews Abraam Mikhael, Co-Founder, Artistic Director & Filmmaker at the Hollywood Arab Film Festival. Abraam talks about his journey from pharmacy and clinical work to film school and festival leadership, and how his Arab, Christian, immigrant background shapes his storytelling. He also shares the mission behind the festival—to bring authentic, human-centered Arab and diaspora stories to Los Angeles—and gives a glimpse into his upcoming production company and debut feature film centered on redemption and spiritual truth. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Mission Matters, ⁠Adam Torres⁠ interviews ⁠Abraam Mikhael⁠, Co-Founder, Artistic Director & Filmmaker at the Hollywood Arab Film Festival. Abraam talks about his journey from pharmacy and clinical work to film school and festival leadership, and how his Arab, Christian, immigrant background shapes his storytelling. He also shares the mission behind the festival—to bring authentic, human-centered Arab and diaspora stories to Los Angeles—and gives a glimpse into his upcoming production company and debut feature film centered on redemption and spiritual truth. Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Family Bible Hour featuring Sam Mikhael

Nessa live, eu conversei com médico Dr. Mikhael Marques (@drmikhaelmarques)Dr. Mikhael Marques é Médico, Palestrante e Escritor. Tem Formações no Brasil, Alemanha e Itália. É Co-fundador do Instituto Olíbano, Fundador da Plataforma de ensino Dose Certa e da Mentoria de Viscum, Dr. Mikhael também é Apicultor e Meliponicultor.Conheça o Clube de Leitura! A Rebelião não é só sobre comida.É sobre consciência. Sobre mergulhar fundo nas ideias que moldam nossa forma de viver, pensar e envelhecer.No Clube de Leitura, exploramos juntos obras que desafiam o senso comum — livros que unem ciência, filosofia e ancestralidade — sempre com uma visão crítica e prática para transformar o conhecimento em ação.

Maka timbullah peperangan di sorga. Mikhael dan malaikat-malaikatnya berperang melawan naga itu, dan naga itu dibantu oleh malaikat-malaikatnya,

Maka timbullah peperangan di sorga. Mikhael dan malaikat-malaikatnya berperang melawan naga itu, dan naga itu dibantu oleh malaikat-malaikatnya,

It's Breast Cancer Awareness Month, and Nicole Mikhael shares her story with us. She had multiple surgeries and full breast reconstruction. See omnystudio.com/listener for privacy information.

Nicole Mikhael On Breast Cancer, Love, Surgery, Turning Recovery Into Business Success + MoreSee omnystudio.com/listener for privacy information.

I dagens samhälle möter unga en komplex verklighet fylld av utmaningar. Hur kan poesin bli ett verktyg för att bearbeta känslor, hantera stress, uttrycka sin identitet och stärka den psykiska hälsan? Vic Vem och Mikhael Mikalides i samtal med Marjut Ervasti, präst Stallarholmen. Medarrangör PP Bokförlag

Dr. Joseph Mikhael, Chief Medical Officer, discusses the IMF's work and what lies ahead in the fight against myeloma. Dr. Mikhael leads the IMF's M-Power Project, which seeks to improve the care delivered to African Americans, who have double the incidence of white people. He spends about 20% of his time in the developing world, seeking ways to enhance access to myeloma therapies in underprivileged countries.

Joseph Mikhael, chief medical officer of The International Myeloma Foundation, and his organization are pulling all the stops to find a true cure for multiple myeloma, a rare and often fatal blood cancer. He shares the origins and mission of the Black Swan Research Initiative, a research project dedicated to preventing myeloma and finding a cure, and how global collaborators are contributing to multiple myeloma research. Also, host Deborah Borfitz delivers the latest news on ChatGPT determining trial eligibility, a questionable shortcut in rectal cancer drug trials, a new no-nausea weight loss remedy heading to trial, and more. News Roundup AI for stratifying Alzheimer's patients Study in Nature Communications  Questionable shortcut in rectal cancer drug trials Investigation in JAMA Network Open ChatGPT determines trial eligibility Paper in Machine Learning: Health Major trauma study to test hemorrhage treatment News release by University of Colorado Anschutz Medical Campus New weight loss remedy soon heads to trials News on Syracuse University website Study in Science Translational Medicine The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

In her new piece, "Home Work," choreographer Maya Brinner invites her two children, Mikhael and Zohar, aged 10 and 7, to turn the stage into an unexpected playful space. Created in the studio amid the ongoing war, the intimate work explores trust, shared space and family. For Brinner, the dance piece bridges two arenas in her life, as a mother and as an artist. Brinner spoke to reporter Naomi Segal about Home Work, with the next performance scheduled for July 24th at the Suzanne Dellal Center in Tel Aviv. (Photo: Efrat Mazor)See omnystudio.com/listener for privacy information.

Wishing Arabs would disappear from Israel, Mikhael Manekin says, is a dangerous fantasy.One of the leaders of Israel's Hasmol Haemuni (Faithful Left) movement, Mikhael is a vocal religious activist for equality and peace. He is the director of the Alliance Fellowship program, an Arab-Jewish political network in Israel, and has authored two books, End of Days Ethics, Tradition, and Power in Israel and Sermons from the Abyss.Mikhael was previously the executive director of Breaking the Silence, an Israeli military veterans' group that seeks "to expose the public to the reality of everyday life in the Occupied Territories." Now, he joins us to answer 18 questions on Israel, including peace, the IDF, and ending the war in Gaza.This interview was held on April 28. Here are our 18 questions:As an Israeli, and as a Jew, how are you feeling at this moment in Israeli history?What has been Israel's greatest success and greatest mistake in its war against Hamas?How have your religious views changed since Oct. 7? What do you look for in deciding which Knesset party to vote for?Which is more important for Israel: Judaism or democracy?Now that Israel already exists, what is the purpose of Zionism?Is opposing Zionism ever antisemitic?Should Israel be a religious state?If you were making the case for Israel, where would you begin?Should all Israelis serve in the army?Is the IDF the world's most moral army?Can questioning the actions of Israel's government and army — even in the context of this war — be a valid form of love and patriotism?What do you think is the most legitimate criticism leveled against Israel today?Do you think the State of Israel is part of the final redemption?Do you think peace between Israelis and Palestinians will happen within your lifetime?What should happen with Gaza and the Palestinian-Israeli Conflict after the war?Where do you identify on Israel's political and religious spectrum, and do you have friends on the “other side”?Do you have more hope or fear for Israel and the Jewish People?

Send us a textWith the Vashjek Inaia leaving... The Orillian Regiment Brigadier has some words for them...Support the show

What's New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Dans cet épisode, on écoute Mikhaël, le premier homme à apporter (seul) son témoignage dans Hors je podcast ! Je sais bien que l'une des "règles" du podcast est de ne recevoir que des femmes mais Mikhaël est venu pour raconter l'histoire d'une femme ; celle de sa petite soeur, qui a été touchée par un cancer rare des os et multi-métastatique à l'âge de 16 ans.Je lui ai piqué un texte que j'ai trouvé magnifique : "Quand on me demande où je puise ma force et ma détermination, la réponse est là, dans ces images.Léna, c'était une joie de vivre intacte malgré les épreuves, une combativité sans faille, et surtout une source d'inspiration pour tous ceux qui se battent. Elle portait en elle lueur d'espoir et une inspiration pour tous les enfants qui luttent chaque jourAujourd'hui, c'est à nous de faire vivre cet espoir. Partageons ce message, sensibilisons et soutenons la lutte contre le cancer pédiatrique. Ensemble, faisons la différence "Bonne écoute !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF's targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding light on specific initiatives aimed at improving access and outcomes. He also dives into his role in medical education, where he mentors the next generation of oncologists through innovative fellowship programs, advancing research, and fostering a more inclusive approach to cancer care. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Paul reopens the Team Sanity/Team Fred discussion during corrections & omissions on Eye of the Beholder. Plus, experiential designer Mikhael Tara Garver chats with Jason & Paul all about the world of large-scale immersive entertainment, her work on the Star Wars Galactic Starcruiser, and the future of immersive at Culture House Media. Oh yeah, and we announce next week's new movie! Tix on sale for Philly live show on Nov 16th and holiday virtual live show on Dec 12th! Go to hdtgm.com for ticket info, merch, and for more on bad movies.Order Paul's book about his childhood: Joyful Recollections of TraumaFor extra content on Matinee Monday movies, visit Paul's YouTube page: youtube.com/paulscheerTalk bad movies on the HDTGM Discord: discord.gg/hdtgmPaul's Discord: discord.gg/paulscheerFollow Paul's movie recs on Letterboxd: letterboxd.com/paulscheer/Check out new HDTGM movie merch over at teepublic.com/stores/hdtgmPaul and Rob Huebel stream live on Twitch every Thursday 8-10pm EST: www.twitch.tv/friendzoneLike good movies too? Subscribe to Unspooled with Paul and Amy Nicholson: listen.earwolf.com/unspooledSubscribe to The Deep Dive with Jessica St. Clair and June Diane Raphael: www.thedeepdiveacademy.com/podcastWhere to find Paul, June, & Jason:@PaulScheer on Instagram & Twitter@Junediane on IG and @MsJuneDiane on TwitterJason is not on social mediaGet access to all the podcasts you love, music channels and radio shows with the SiriusXM App! Get 3 months free using the link: siriusxm.com/hdtgm.

Jill and Tom are Joined in-studio by Brendan Appel this week. In the first segment Jill and Brendan respond to Tom's impressions of the updated Genesis GV80 midsize crossover. The trio also discussed the pending engine-replacement recall facing owners of all 2022 and 2023 Toyota Tundras. The recall is reportedly going to require up to 24 hours of labor per vehicle. Still in the first segment, Jill reviews the 2024 AMG Mercedes-Benz GLC 43 Coupe. Jill was generally impressed by the “coupe” version of Mercedes' compact crossover. Listen in for her complete take. In the second segment, the hosts welcome Mikhael Farah of Rivian to the program. Mikhael walked the crew through a number of news items, including Volkswagen's investment in Rivan, coming small and subcompact Rivian crossovers, and the updated-for-2025 R1S and R1T models, which are on sale now. In the third segment, Jill and Brendan are subjected to Tom's “Porsche Price” quiz. 

"I tend to treat my life with an open hand. Don't hold things too tightly. Whatever happens happens, I'm only 36. I've lived a full life."Rony Mikhael shares his journey as an immigrant creative, from his early days in Kuwait to building a successful career in Canada. He discusses the challenges of adapting to a new culture, finding his passion in design, and developing a versatile skill set across various creative disciplines. Rony emphasizes the importance of embracing opportunities, stepping out of one's comfort zone, and maintaining an open mindset throughout one's career.Takeaways:Adaptability is crucial for success, especially for immigrant creatives.Developing a diverse skill set can lead to unique opportunities and perspectives in the creative field.Embracing challenges and stepping out of your comfort zone can lead to personal and professional growth.Maintaining an open mindset and following opportunities can lead to unexpected and rewarding experiences.Finding contentment in your journey is important, rather than rigidly adhering to a predetermined path.Practical experience and curiosity can be more valuable than formal education in some creative fields.Building a strong foundation in various creative disciplines can enhance one's ability to lead and communicate effectively as a creative director.It's essential to find fulfillment in your work rather than simply following trends or niching down for the sake of it.Creativity For Sale: How to start and grow a life-changing creative career and business by Radim Malinic - Out now. Paperback and Kindlehttps://amzn.to/4biTwFcFree audiobook (with Audible trial)https://geni.us/8r2eSAQSigned Bookshttps://novemberuniverse.co.uk

In this one, we are going to talk about how to achieve BALANCE in your running in two different ways. a. How do you balance running and life? I give you 5 thoughts on how to find time for training while balancing work, family, and relationships. b. How do you balance finding the edge in performance with overall health? I give you 5 thoughts on how to find and test your limits without sacrificing long term health and longevity. Balance isn't easy and requires constant work, but I hope these ideas will help you get the yin and yang right for you. Thank you to Logan and Mikhael for the show ideas that sparked this episode! To redeem the offer from this episode's sponsor, use the code ROGUE for 10% off on running apparel at Janji.com.

Pentecost was powerful, but it took longer to arrive than some expected. The lost art of waiting is the topic of this episode, and is sure to challenge you. Listen as Rev. Berrier tells us why patience is the key to your next level of growth.   #KingdomSpeak  #Podcast #Patience

The Architect's Guide to NKBA MembershipJoin Mark in this episode as he interviews Andrew Mikhael, an architect with over 20 years of experience, who shares his journey from discovering his passion for architecture to starting his own practice.Andrew emphasizes the transformative power of architecture, aiming to imbue everyday activities with wonder and ease, creating what he terms the "Luxury of the Senses." As President Elect of the National Kitchen and Bath Association Olympic and West Sound Chapter, Andrew highlights the benefits of NKBA membership for architects and stresses the importance of defining a vision for the future.With a Master's of Architecture from the University of Pennsylvania and a Bachelor's from the New Jersey Institute of Technology, Andrew is a licensed architect registered in multiple states and an active member of the design community. His work has been featured in prestigious publications and exhibitions, reflecting his passion for bi-coastal projects in NYC and the greater Seattle region.Beyond architecture, Andrew's interests include cooking, chess, cello, meditation, and gardening in the Pacific Northwest. Tune in to gain insights into Andrew's journey and his vision for the future of architecture.This week at EntreArchitect Podcast, The Architect's Guide to NKBA Membership with Andrew Mikhael.Connect with Andrew online at Andrew Mikhael Architect, learn more about the NKBA, and find him on LinkedIn.Please visit Our Platform SponsorsMGS Global Group can lighten your load by handling all of your drafting and rendering needs. They work is an extension of your team and follow your standards to ensure the quality and accuracy of your drawings. Visit mgsglobalgroup.com and book your free consultation today.ARCAT's SpecWizard™ is the tool that will help you save time writing specifications. It's a free, patented tool that allows you to select products and options error free and generate a three part specification in minutes. Go to ARCAT.comand try SpecWizard™ today.Visit our Platform Sponsors today and thank them for supporting YOU... The EntreArchitect Community of small firm architects.

Don't miss The Balm In Gilead's  Multiple Myeloma Spotlight on our website!This week's guest, Dr Joseph Mikhael MD, MEd, FRCPC, FACP,  leads the M-Power project in the African American community for the International Myeloma Foundation (IMF). Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is the Chief Medical Officer of the IMF and Director of Myeloma research at the HonorHealth Research Institute. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom's macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr. Mikhael also serves as the Treasurer on the executive board of the American Society of Hematology. Dr Mikhael has published over 200 peer-reviewed articles in these fields, and lectures internationally on a regular basis.  He is also the chair of the Diversity, Equity and Inclusion Council at TGen.  Dr. Mikhael is heavily involved in training future researchers, and mentors junior faculty worldwide.  He also spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel treatment agents.

In der letzten Episode haben wir über das Thema Selbstgespräche geredet und eine Umfrage gestartet, bei der herausgekommen ist, dass zwei Drittel unserer Mitglieder manchmal laut mit sich selbst sprechen. Janusz springt heute für Manuel ein und erzählt, ob auch er ab und zu Selbstgespräche führt. Im Anschluss beantworten Cari und Janusz zwei Hörerfragen und erklären, wann man das Wort "halt" benutzt und was sie von Einkaufszentren halten. Morgen, am Mittwoch, den 21.02.2024 um 19 Uhr (Berlin) sind wir wieder live auf unserem Easy German YouTube-Kanal. Finde hier deine lokale Uhrzeit: Zeitzonenrechner   Transkript und Vokabelhilfe Werde ein Easy German Mitglied und du bekommst unsere Vokabelhilfe, ein interaktives Transkript und Bonusmaterial zu jeder Episode: easygerman.org/membership   Sponsoren Hier findet ihr unsere Sponsoren und exklusive Angebote: easygerman.org/sponsors   Follow-up Na? (Easy German Podcast 458)   Eure Fragen Bruce fragt: Wann benutzt man das Wort "halt"? HALT + EBEN - German Modal Particles Explained (Super Easy German 197) Doch, Halt, Mal, Eben & Ja - German modal particles explained! (Easy German 231) Mikhael aus Moskau fragt: Was halten wir von Einkaufszentren? Hast du eine Frage an uns? Auf easygerman.fm kannst du uns eine Sprachnachricht schicken.   Wichtige Vokabeln in dieser Episode verhindert sein: bedeutet, dass jemand nicht in der Lage ist, an einer Aktivität oder einem Ereignis teilzunehmen das Selbstgespräch: Akt des Sprechens mit sich selbst, oft als Mittel zur Selbstreflexion oder Problemlösung das Äquivalent: etwas, das den gleichen Wert, die gleiche Bedeutung oder Funktion wie etwas anderes hat peinlich berührt sein: Gefühl der Unbehaglichkeit oder Verlegenheit, oft aufgrund einer unangenehmen Situation oder eines peinlichen Fehlers die Modalpartikel: Art von Wort in der deutschen Sprache, das verwendet wird, um die Stimmung oder Haltung des Sprechers auszudrücken, ohne die grundlegende Bedeutung des Satzes zu ändern, z. B. "halt" das Einkaufszentrum: großes Gebäude oder Komplex, der viele verschiedene Geschäfte und Dienstleistungen beherbergt   Support Easy German and get interactive transcripts, live vocabulary and bonus content: easygerman.org/membership

This is the second part of an incredible conversation with Mikhael Tara Garver. If you haven't listened to part 1 yet, go back and give it a listen!!!Mikhael is currently Head of Immersive Entertainment for Culture House Media but from July 2021 to March 2022, she served as the Director of Immersive Experience for Star Wars: Galactic Starcruiser at Walt Disney World. In this role, she helped write the show, choreographed galactic superstar Gaya, and trained & directed the opening cast. In this second portion of our conversation, she chatted with us about how many folks on the team knew that this experience would stick with us, several tricks of the immersive entertainment trade, and other bits of magic.Support the showHeroes of the Halcyon on InstagramTheme Music ("Digital Discourse") by Yellow BarrelSend your email to heroesofthehalcyon@gmail.com - we'd love to hear from you about your journeys, episode suggestions, or just to say hi!

This is the first part of an incredible conversation with Mikhael Tara Garver.Mikhael is currently Head of Immersive Entertainment for Culture House Media but from July 2021 to March 2022, she served as the Director of Immersive Experience for Star Wars: Galactic Starcruiser at Walt Disney World. In this role, she helped write the show, choreographed galactic superstar Gaya, and trained & directed the opening cast. In this first portion of our conversation, she chatted with us about her background, how she joined the leadership team of Star Wars: Galactic Starcruiser, how the team worked together behind the scenes, and so much more.Bleep bloop Star Wars. It'll make sense when you listen. :)Support the showHeroes of the Halcyon on InstagramTheme Music ("Digital Discourse") by Yellow BarrelSend your email to heroesofthehalcyon@gmail.com - we'd love to hear from you about your journeys, episode suggestions, or just to say hi!

In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.

Rob Lee is a Baltimore-based journalist and podcaster who hosts The Truth in this Art podcast. The podcast explores contemporary art and cultural preservation through conversations with artists, curators, and cultural leaders. The podcast also occasionally interviews friends in other industries such as acting, music, and journalism. The Truth In This Art explores Baltimore and beyond including Washington DC, Philadelphia, New Orleans and more. Visit the website for the entire archive - https://www.thetruthinthisart.com/ Visit our Youtube Channel for the video experience - https://www.youtube.com/channel/UC55X_osEdwOUU2sQwRBFI1w -- Join us on The Truth in This Art Podcast

TMBS 122 aired on Jan 7, 2020 Episode summary: The crisis in Australia & moving toward a GND.  Shoutout to the Center-Left in Portugual, for showing an alternative to right-wing populism.  Dr. Drew Mikhael (@DrDrewMikhael) joins us to talk about the crisis with Iran and provides a deeper understanding of the social movement in the country.  During the GEM, How Banks prey on the poor and how to end it?  Matt Christman (@CushBomb) joins us to talk about Iran, Warren, and The View.  TMBS ReAirs come out every Tuesday here and on The Michael Brooks Show YouTube Channel. This program has been put together by The Michael Brooks Legacy Project. To learn more and rewatch the postgame and all other archived content visit https://www.patreon.com/TMBS  The TMBS ReAir project was created to give people who discovered Michael's work towards the end of his life or after his passing a weekly place to access his work without feeling overwhelmed by the volume of content they missed, as well as continuing to give grieving friends, family and fans their Tuesday evenings with Michael. While the majority of the content and analysis on TMBS has stayed relevant and timeless, please remember some of the guest's work and subject matter on the show is very much linked to the time when the show first aired. The appearance of some guests on TMBS does not constitute an endorsement of those guests' current work.

Aimee Rinehart of the Associated Press and Mikhael Simmonds, Executive Director at the Center for Community Media at CUNY will lead a discussion on Artificial Intelligence (AI) and Comms4Good.

As people of The Name, we must have an understanding of the blessing we possess. All of the patriarchs of old never had His name revealed to them. The invoking of the name of Jesus brings power, healing, and deliverance in our lives!09/17/2023 - Sunday NightScriptures Used (In Order of Occurrence):Philippians 2:5-11Ephesians 1:20-23John 1:1-4, 14John 4:7-17, 24-26John 14:8-10

Just one moment in the presence of God Almighty has the power to change everything. When you come in contact with Him, you don't have to be the same anymore. It is your level of desire and desperation in this moment that will get God's attention. 09/17/2023 - Sunday Morning Scriptures Used (In Order of Occurrence):Mark 2:1-12

Explore creativity where it meets business insight on 'The Truth In This Art Podcast'. I'm Rob Lee, and today, we're journeying with Alexi Abi Mikhael, a visual artist from the DMV area, whose abstract artwork marries diverse cultural influences. Drawing from her Middle Eastern heritage, she crafts compelling masterpieces unlike any other."Alexi Abi Mikhael's journey in abstract art is a story of talent, art therapy, and entrepreneurial spirit. From finding art as a healing tool during high school to embracing inspiration from greats like Andy Warhol and Van Gogh, her work is imbued with emotion and personal experiences. In this episode, she emphasizes collaboration and adaptability in the art industry, giving us insights into her future ventures, including teaching art and participating in festivals. Dive into the conversation with an artist who skillfully unites therapy, art, and business.Inside this recording, we venture into: Alexi's early experiences with art during high school, where she discovered its power as a form of therapy. Explore how creative expression can serve as a means of coping during challenging times and how it has shaped her artistic journey. How Alexi's Middle Eastern heritage influences her abstract artwork. Discover how she skillfully weaves together diverse cultural inspirations, bringing a unique and captivating dimension to her creations. The intricate relationship between emotions and art in Alexi's work. Uncover the ways in which she employs colors, shapes, and lines as her emotional toolkit, allowing her to communicate a wide range of feelings and experiences through her abstract pieces. The dynamic world of collaboration and adaptability within the art industry. Learn from Alexi's insights on why these qualities are crucial for artists to succeed, and how remaining open to learning and collaboration can enhance creativity and growth. Her plans for teaching art classes and participating in art festivals, gaining valuable insights into her aspirations, teaching philosophy, and the exciting events she's preparing to engage in. Join me in this inspiring conversation with Alexi Abi Mikhael as we delve into the vibrant world of abstract art, art therapy, and entrepreneurship. You don't want to miss it!

STRONG Life Podcast ep 389 Avoid these MISTAKES in High School Strength & Conditioning ft JP Mikhael M3 Strength & Conditioning Watch on YouTube: https://youtu.be/lvt3ZlCg3ac  Connect with JP Mikhael: https://www.instagram.com/m3strengthandconditioning/ Strength Coach Certifications from Zach: http://SSPCoach.com http://UndergroundStrengthCert.com  BOTH Certifications have Business Bonuses and Seminar Recordings with Matt Wenning  FREE Training Courses - http://ZachStrength.com  Strength Training for Men Over 35 - https://zacheven-esh.com/strong-lean-men-over-35/ 

INSIDER: https://bit.ly/Lutz_Insider e use o cupom LUTZ12 para 12% de desconto em todo site Mikhael Marques é médico, palestrante, professor, escritor e fundador do @institutoolibano. @drmikhaelmarques Como fiz mais de 1 milhão de reais no YouTube fazendo o que eu amo: https://dominando.co/dyt AS MELHORES PARTES DOS PODCASTS: Cortes do Lutz: https://www.youtube.com/@CortesdoLutzOFICIAL LINKS DO EPISÓDIO: Insta do Mikhael: https://www.instagram.com/drmikhaelmarques/ Instituo Olíbano: https://www.instagram.com/institutoolibano/ PUBLICIDADE: Entre em contato: comercial@lutzpodcast.com REDES SOCIAIS: Instagram do Lutz: https://instagram.com/lutzlobo Instagram do Podcast: https://instagram.com/lutzpodcast

Please visit answersincme.com/EUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology and oncology discuss the role of cereblon E3 ligase modulators in patients with relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating cereblon (CRBN) E3 ligase modulators (CELMoDs) as therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM); Describe the clinical profiles of emerging CELMoDs for patients with RRMM; and Outline evidence-based strategies to optimize sequencing to CELMoDs for patients with RRMM, as they become available.

In this episode, I sat down with Dr. Bassem Mikhael, SVP, of the Clinical Enterprise at Somatus. Started in 2016 by Dr. Ikenna Okezie, Somatus partners with clinicians, health plans, health systems, and multi-disciplinary community-based care teams to improve health, quality of life, and cost of care for patients with kidney disease. Somatus employs over 1,450 team members and serves more than 150,000 patients across 36 states. Dr. Mikhael and I discuss: 1) The vital role that kidneys play in maintaining health, the issues that arise from diseased kidneys, and how these challenges translate into per patient costs that are 10x higher, on average, than those for patients without kidney disease, 2) The traditional model for treating patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) and how Somatus' model realigns incentives to focus on integrated, preventative, and patient-centered care, 3) Why the federal government, CMS, and CMMI have prioritized investments in kidney care and what we've learned from their initiatives and care model tests, and 4) Clinical innovations that make Dr. Mikhael optimistic about the future for patients living with kidney disease.

BONUS STRONG Life Podcast  Josh Bryant & JP Mikhael discuss Prison Strength Training & Business Lessons that JP learned while serving 9 years in prison.  Connect with Josh: https://JoshStrength.com Connect with JP: https://m3strengthandconditioning.com/  Brought to you by http://ZachStrength.com (FREE Strength Training Courses) JP and Josh discuss the following topics: Bodyweight Training / Calisthenics lessons learned in Prison Business / Communication skills that JP learned in prison and allowed him to build a thriving personal training / strength and conditioning business  The CRAZY Burpee challenge JP learned in prison  The Power behind calisthenics for ALL age groups  Nutrition tips for Bulking and Fat Loss from prison  How JP teaches adults to eat when they are pushing for fat loss Plus much more! This was VERY inspiring and informative.  Keep crushing those 5 star reviews!!! Resources: http://BodyweightBodybuilding.com STRONG & Lean Over 35 (Only $7) Gladiator STRONG - 7 Days FREE

"Your Victory Is In Your Voice" | Evangelist Mikhael Berrier | Sunday Service | 01/29/2022 In this live-streamed service, Evangelist Mikhael Berrier preaches from Psalm 47 : 1 on the subject: "Your Victory Is In Your Voice." If you'd like to hear more message replays from our Church, subscribe to our podcast To learn more about our church, please visit our website at: https://www.conyersapostolicchurch.com If you'd like to learn more about the Apostolic doctrine, join our FREE online resource at https://www.deeperlifestudies.com To submit a prayer request to our Prayer Partners Team, you can do so at: https://conyersapostolicchurch.com/prayer-requests To obtain a personal Bible Study, submit a request here: https://forms.gle/egRu8ysswVS3mYxA9 May God richly bless you!

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 1: Optimizing the Current Management of Multiple Myeloma (MM) — Dr Joseph Mikhael CME information and select publications

This week, Michelle chats with Mikhael Porter, CEO and co-founder of Needle Music. Needle is social network dedicated to connecting you to favorite artists and other fans.Connect with Needle:needlemusic.coIG: @needle.musicConnect with us:betterbeings.netIG: @be.a.better.beingMichelle: @betterbeingsusSasha: @sasha.patriciaYouTube: Michelle Zellner - Be A Better Being Podcast playlist

Unless you've been living in another galaxy, far, far away, you know that immersive entertainment is exploding… And this week's guest Mikhael Tara Garver is one of the pre-eminent thought leaders in immersive entertainment and original experiential performances.  Her most recent project made headlines everywhere She was the Director of Immersive Experience for Disney's Star Wars: Galactic Starcruiser. Immersive work requires ALL KINDS OF CREATIVES: filmmakers, digital artists, designers (costume, game, sound, lighting), dramaturgs, UX designers, writers, composers, and musicians (and that list is by no means exhaustive!). So if you want to make money doing your creative thing, you'll love this mind-blowing conversation about the new frontier of live performance.  Mikhael's work has been seen in some fancy spaces! The Kennedy Center, The Goodman Theater, The United Nations, and Boston's Institute of Contemporary Art… and you might know her work as the director of The American Repertory Theater's production of Sleep No More. And her take on immersive experience will touch you: She believes immersive work (at it's best) is meant to make audience members feel seen and heard (wait til you hear her heartbreakingly beautiful story about a veteran's experience on the Starcruiser). Oh, and if you geek out over holistic experiences, sci-fi, or Star Wars, then this episode is a must-listen! Thank you for tuning in to this episode of Brian Breaks Character!   If you loved this episode, please subscribe and leave an honest review. Your review helps boost the show and gives us the chance to help more creatives get out of suffering for their art and into action. Be sure to leave your IG handle when you do so I can send a VIP episode to say thank you.   CONNECT WITH MIKHAEL Instagram  https://www.instagram.com/mtgexperience Website https://www.mikhaeltaragarver.com   Subscribe To The Podcast https://podcasts.apple.com/podcast/id1570747490   Watch The Uncut Behind-the-scenes Video Of This Episode On YouTube: https://www.youtube.com/user/brianpatacca   Need New Representation? Get In On This Free Training: https://makeagentswantyou.com   Follow Me On Instagram For A First-look At Our Guests And Upcoming Episodes! https://www.instagram.com/briansaysthat Episode Transcript https://brianbreakscharacter.s3.us-west-2.amazonaws.com/Ep.+90+-+Pioneering+Experiential+Entertainment+with+Star+Wars+Galactic+Starcruiser+Immersive+Director+Mikhael+Tara+Garver+-+Transcript.pdf 

Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.

Ever wanna hear what songs your favorite athlete listens to psych themselves up before the match?The tunes your favorite artist spins to inspire their next creation?Chatting with Mikhael Porter, co-founder of Needle Music this week about the socialization of music, the rise of the music influencer, and creating a social network built for both the music artist and the music curator to thrive.Check out more on Mikhael Porter & Needle Here:https://apps.apple.com/us/app/needle-music/id1539883285https://twitter.com/MikhaelPorterCheck out more from the Pop-Marketer here:https://qrco.de/bcI85K

Mikhael has reimagined what social media can be with Needle Music, the world's first social platform built to facilitate meaningful connections through music. Despite all the negative effects that social media has on one's mental health, Mikhael is a firm believer in its positive power. Needle is the perfect case study, bringing together consumers and influencers in a space that rewards both parties for their interactivity. They've placed an emphasis on TikTok marketing, and Mikhael hopes to ride the wave of creator empowerment that the platform has ushered in.Guest:Mikhael Porter - LinkedInNeedle MusicTikTok - @needle.musicInstagram - @needle.musicDownload the Needle Music on the IOS or Android App Store Today!The Future Is FreelanceThis show is for freelancers, sole traders, solopreneurs, digital nomads, consultants,...Listen on: Apple Podcasts SpotifySupport the show

Mikhael Porter, co-founder and CEO of the social media platform Needle Music, discusses how the idea of a digital community oriented around music came about during the COVID-19 pandemic. Why music serves as a special means of bringing people together and the features of Needle Music not seen elsewhere are key areas of our discussion.  If you are a music fan or someone looking for an alternative social media platform to connect with others, this is one conversation you do not want to miss out on. To learn more about Needle Music, check out https://www.needlemusic.co.

Good Afternoon and welcome to another episode of #sportsbizmusic the podcast and on today's show I got the chance to sit and chat with Mikhael Porter Co-Founder of Needle Music. Needle is a social audio experience that streamlines the way you share and discover music. Find songs through your friends, celebrities, artists, and most trusted curators, on a platform that breeds positivity and connectivity. Check out Needle Music today!: https://www.needlemusic.co